The market for biologics to treat severe eosinophilic asthma may just have got more competitive, with the UK’s National Institute for Health and Care Excellence (NICE) asking for clarifications and updated cost-effectiveness analyses in its draft guidance for Teva Pharmaceutical Industries Ltd.’s intravenous administered humanized interleukin-5 antagonist MAb Cinqaero (reslizumab).
Cinqaero was launched in the UK this summer for use as add-on therapy in adult patients with severe eosinophilic asthma,...



